Saama, a provider of AI- and ML-based solutions that accelerate clinical development and commercialization, announced today the launch of its unified platf...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with canc...
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the F...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial1 is being led by Lanhzou Biotechnique Development wi...
The record date will be 5 p.m. Burlington, North Carolina time on Tuesday, June 20, 2023, and The distribution date will be 11:59 p.m. Burlington, North...
SciTech Development today announced it has closed a $2.73M funding round, led by several prominent life science investors to advance clinical trials for No...
Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clini...
Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform techn...
New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, Texas Enrolment now open to patient...
HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated fro...
© 2025 Biopharma Boardroom. All Rights Reserved.
